Adamis Pharms Corp Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ADAMIS PHARMS CORP, and when can generic versions of ADAMIS PHARMS CORP drugs launch?
ADAMIS PHARMS CORP has two approved drugs.
There are three US patents protecting ADAMIS PHARMS CORP drugs.
There are forty patent family members on ADAMIS PHARMS CORP drugs in seventeen countries and one supplementary protection certificate in one country.
Summary for Adamis Pharms Corp
International Patents: | 40 |
US Patents: | 3 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
Drugs and US Patents for Adamis Pharms Corp
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adamis Pharms Corp | SYMJEPI | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 207534-001 | Jun 15, 2017 | RX | Yes | Yes | 11,141,540 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Adamis Pharms Corp | ZIMHI | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 212854-001 | Oct 15, 2021 | RX | Yes | Yes | 11,571,518 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Adamis Pharms Corp | ZIMHI | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 212854-001 | Oct 15, 2021 | RX | Yes | Yes | 11,027,072 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Adamis Pharms Corp | SYMJEPI | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 207534-002 | Sep 27, 2018 | DISCN | Yes | No | 11,141,540 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Adamis Pharms Corp Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Spain | 2926913 | ⤷ Sign Up |
South Korea | 102547538 | ⤷ Sign Up |
Portugal | 3341056 | ⤷ Sign Up |
Hong Kong | 1257820 | ⤷ Sign Up |
New Zealand | 754639 | ⤷ Sign Up |
Hong Kong | 1254290 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Adamis Pharms Corp Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1685839 | 92292 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.